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Abstract
Background: Cerebral oedema is associated with significant neurological damage in patients with
traumatic brain injury. Bradykinin is an inflammatory mediator that may contribute to cerebral
oedema by increasing the permeability of the blood-brain barrier. We evaluated the safety and
effectiveness of the non-peptide bradykinin B2 receptor antagonist Anatibant in the treatment of
patients with traumatic brain injury. During the course of the trial, funding was withdrawn by the
sponsor.
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Methods: Adults with traumatic brain injury and a Glasgow Coma Scale score of 12 or less, who
had a CT scan showing an intracranial abnormality consistent with trauma, and were within eight
hours of their injury were randomly allocated to low, medium or high dose Anatibant or to placebo.
Outcomes were Serious Adverse Events (SAE), mortality 15 days following injury and in-hospital
morbidity assessed by the Glasgow Coma Scale (GCS), the Disability Rating Scale (DRS) and a
modified version of the Oxford Handicap Scale (HIREOS).
Results: 228 patients out of a planned sample size of 400 patients were randomised. The risk of
experiencing one or more SAEs was 26.4% (43/163) in the combined Anatibant treated group,
compared to 19.3% (11/57) in the placebo group (relative risk = 1.37; 95% CI 0·76 to 2·46). All
cause mortality in the Anatibant treated group was 19% and in the placebo group 15.8% (relative
risk 1.20, 95% CI 0.61 to 2.36). The mean GCS at discharge was 12.48 in the Anatibant treated
group and 13.0 in the placebo group. Mean DRS was 11.18 Anatibant versus 9.73 placebo, and mean
HIREOS was 3.94 Anatibant versus 3.54 placebo. The differences between the mean levels for GCS,
DRS and HIREOS in the Anatibant and placebo groups, when adjusted for baseline GCS, showed a
non-significant trend for worse outcomes in all three measures.
Conclusion: This trial did not reach the planned sample size of 400 patients and consequently, the
study power to detect an increase in the risk of serious adverse events was reduced. This trial
provides no reliable evidence of benefit or harm and a larger trial would be needed to establish
safety and effectiveness.
Trial Registration: This study is registered as an International Standard Randomised Controlled
Trial, number ISRCTN23625128.
Background
Cerebral oedema is associated with significant mortality
and morbidity after traumatic brain injury (TBI). It devel-
ops soon after injury, reaching a maximum between 3 and
5 days post injury [1]. An increase in the permeability of
the blood-brain barrier (BBB) is believed to be responsi-
ble for oedema formation. Bradykinin (BK), an inflamma-
tory mediator in the kinin-kallikrein system, may
contribute to cerebral oedema by increasing permeability
of the BBB. BK is produced immediately after injury and
appears to be a potent endogenous disruptor of the BBB
[2]. BK increases the permeability of the BBB to small sol-
utes and increases blood pressure in the microcirculation
due to arterial vasodilatation and venous constriction [3].
Levels of BK1-5, a stable circulating metabolite of systemic
BK in humans, have been shown to decrease steeply
within the first 80 hours after TBI [4].
Bradykinin B2 receptor antagonists (BB2) block the activ-
ity of the kinin-kallikrein system, preventing the release of
BK, and may reduce neuronal damage after TBI [5]. A sys-
tematic review of controlled studies in animal brain injury
models showed that BB2 antagonists reduce brain
oedema and improve neurological outcome [6]. A system-
atic review of randomised trials of BB2 antagonists in TBI
patients found three small trials with a total of 178 partic-
ipants and provided no reliable evidence of either benefit
or harm. There were, however, non-significant reductions
in mortality and disability with BB2 antagonists [7].
Anatibant, a non-peptide, selective BB2 antagonist,
reduces brain oedema in animal TBI models [8-11]. No
serious toxicity was found in Phase 1 clinical trials [4,12].
Following subcutaneous administration of clinically rele-
vant doses, there were no systemic effects but there was
pain, inflammation and nodule formation at the injection
site.
Anatibant inhibits the binding of BK to the B2 receptor.
After subcutaneous injection Anatibant is bio-available
and crosses the BBB. Pharmacokinetic (PK) studies show
brain interstitial fluid levels in excess of the concentration
required to produce half maximum inhibition at the B2
receptor. Anatibant has a plasma half-life after subcutane-
ous administration of 30 and 70 hours in healthy volun-
teers and TBI patients respectively and can be given as a
once daily subcutaneous injection. Metabolism and excre-
tion is mainly through hepatic and biliary routes. PK
parameters are increased 1.5-2 fold in TBI patients com-
pared to healthy volunteers, possibly due to decreased
hepatic clearance [4,12].
Because plausible treatment effects in TBI are likely to be
modest, we planned to conduct a large phase III trial with
at least five thousand patients. As a prelude to this, we set
out to conduct a phase II trial of 400 patients to assess
safety and to inform the dose selection for the phase III
trial.Trials 2009, 10:109 http://www.trialsjournal.com/content/10/1/109
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Methods
All collaborating investigators were required to secure the
relevant ethics and regulatory approvals before recruit-
ment could begin. Consent was obtained in accordance
with the requirements of each ethics committee.
Eligibility
All non-pregnant adults (ages 16 to 65 years inclusive)
with a traumatic brain injury, who had a score on the
Glasgow Coma Scale (GCS) of 12 or less (out of a maxi-
mum score of 15) and who had a CT scan showing an
intracranial abnormality consistent with trauma, and
were within eight hours of their injury, were eligible for
trial entry if the responsible doctor considered there was
the potential for them to benefit from the trial treatment.
Patients known to have been treated with another investi-
gational drug therapy within 30 days of injury were
excluded.
Intervention
Patients were randomly allocated to receive a low (10 mg
loading dose and 5 mg/day), medium (20 mg loading
dose and 10 mg/day) or high (30 mg loading dose and 15
mg/day) dose of Anatibant or matching placebo. The
loading dose was given as soon as possible and within 8
hours of injury and administered as two simultaneous
subcutaneous injections of 5 mg, 10 mg and 15 mg
respectively. The maintenance dose was given 24 hours
after the loading dose and continued daily for 4 days.
Study objectives
The primary study objective was to compare the propor-
tion of patients with at least one SAE in those receiving
Anatibant and those receiving placebo. The secondary
study objectives were to assess the effect of Anatibant on
early mortality and morbidity and to establish the dose to
be used in the phase III trial. Samples for pharmacokinetic
analyses were collected but these data are not reported
here.
Study outcomes
A Serious Adverse Event (SAE) was defined as any unto-
ward medical occurrence that was (1) fatal; (2) life threat-
ening; (3) required or prolonged hospitalisation; (4)
resulted in persistent or significant disability or incapac-
ity; (5) medically significant in that it may jeopardise the
patient and may require medical or surgical intervention
to prevent one of the outcomes listed above; or (6) con-
genital anomalies. Medical occurrences that were expected
in the course of traumatic brain injury, or which were
known to occur during routine diagnostic or therapeutic
procedures, were excluded. Any SAE occurring after the
administration of the first dose of study medication and
up to 15 days following injury was included. Mortality
was assessed up to 15 days following the injury. In-hospi-
tal morbidity was assessed 15 days after injury or at with-
drawal using the Glasgow Coma Scale (GCS), the
Disability Rating Scale (DRS) and a modified version of
the Oxford Handicap Scale which is referred to here as the
Head Injury Related Early Outcome Score (HIREOS).
Sample size
We planned to randomise a total of 400 patients, 100 to
each of the four groups. Assuming that the proportion of
patients with at least one SAE would be 20% in the pla-
cebo group, the trial would have had 90% statistical
power to detect a doubling of this proportion (to 40%) in
the combined Anatibant groups using a 1-sided signifi-
cance level of 5%. A 1-sided test was considered appropri-
ate since a decision to not continue to a Phase III trial
would only have been taken if the proportion of patients
with at least one SAE had been higher in the combined
Anatibant groups.
Randomisation
Randomisation was done centrally by Sealed Envelope
Ltd, UK, using an Interactive Voice Response System
(IVRS). Initial patient information confirming eligibility
was first collected via the IVRS. The central study compu-
ter then randomly assigned a treatment pack number cor-
responding to one of a number of blinded treatment
packs available in the emergency department of the partic-
ipating hospital. The information collected was used to
achieve balance with respect to key prognostic factors
using minimisation on the basis of the following varia-
bles: sex, age (16 to ≤40; >40 to ≤50; >50 to ≤65), time
since injury: (≤1 h, >1 to ≤3 h, >3 to ≤8 h); GCS: 3 to 5; 6
to 8; 9 to 12; and pupil reactivity (both, one or none).
Blinding
Active drug and placebo were visually matched and
packed by an independent clinical trials supply company,
Bilcare, UK. All study personnel and participants were to
be blinded to treatment assignment for the duration of
the study. Only the independent Data Safety Monitoring
Board (DSMB) and their independent statistician were to
see un-blinded data but none had any contact with study
participants.
Statistical methods
All data analyses were carried out according to a pre-
defined statistical analysis plan. Both intention-to-treat
and per-protocol analyses were undertaken. As per the
analysis plan the primary analyses reported here compare
results in the combined Anatibant groups with those in
the placebo group. Because the trial stopped early, formal
statistical comparisons between dose groups, although
specified in the analysis plan, are not reported here. In
addition, for the updated meta-analysis of effect of Brady-
kinin B2 receptor antagonists on mortality after TBI, theTrials 2009, 10:109 http://www.trialsjournal.com/content/10/1/109
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relative risks (RR) and 95% confidence intervals (CIs) for
mortality were calculated for each trial and pooled using
the fixed-effect model.
The proportion of patients with at least one SAE in the
combined Anatibant groups was compared with that in
the placebo group using a Fisher's exact test. The relative
risk and 95% confidence interval were also calculated. The
result was declared significant if the p-value was less than
0.05 (1-sided test).
All cause mortality in the period up to and including 15
days post randomisation was compared using Fisher's
exact test. GCS, DRS and HIREOS scores at 15 days post
randomisation were compared using an analysis of covar-
iance model to adjust for baseline GCS scores. Since these
variables are not normally distributed, non-parametric
bias-corrected and accelerated 95% bootstrap confidence
intervals (2,000 replications) were computed and used to
infer statistical significance at the 5% level [13]. No sub-
group analyses were planned or performed because it was
considered that there would be insufficient power to
detect plausible levels of interaction.
Safety Monitoring
During the trial, interim analyses of all data including
SAEs, mortality and morbidity were carried out by an
independent DSMB. The DSMB had the responsibility for
deciding whether, while recruitment was in progress, the
un-blinded results (or the un-blinded results for a partic-
ular subgroup), should be revealed to the Trial Steering
Committee (TSC). Because the trial was collecting data on
a range of potential safety end points and it would have
been impossible to specify in advance the potential
adverse effects, there were no formal stopping rules.
Instead, the DSMB was required to reveal the un-blinded
results to the TSC if, taking into account both statistical
and clinical issues and exercising their best clinical and
statistical judgement, the un-blinded results provided suf-
ficient evidence that the trial treatment was on balance
harmful for all, or for a particular category of patients.
Role of the funding source and other relevant 
organisations
Xytis Pharmaceutical Sarl (Switzerland) was legal sponsor
and funder and was involved in the development of the
protocol. Xytis had one non-voting representative on the
TSC but did not contribute to this data analysis. The TSC
provided overall supervision of the trial. In particular, the
TSC concentrated on the progress of the trial, adherence to
the protocol, patient safety and consideration of new
information. The trial was coordinated and managed by
the London School of Hygiene & Tropical Medicine
(LSHTM).
Results
The first patient was enrolled in March 2007. On 1
November 2007, after reviewing un-blinded data on 140
patients, the DSMB disclosed limited un-blinded results
to the TSC because of patient safety concerns. By that time
a total of 228 patients had been randomised. The TSC sus-
pended recruitment until a review of the data on all 228
patients could be undertaken by the DSMB. Presentation
of this data to the DSMB was delayed due to a legal dis-
pute between LSHTM and Xytis which was heard in the
High Court of London in March 2008. The DSMB finally
reviewed the data on 6 June 2008 and recommended that
recruitment could recommence. After funding was with-
drawn the trial was terminated.
In the course of the trial a number of protocol deviations
occurred, including LSHTM not receiving all trial data and
information on SAEs. LSHTM withdrew Clinical Research
Associates' (CRA) access to the clinical trial database for a
period of time when this occurred. In addition, the High
Court of Justice in London granted an injunction prevent-
ing the TSC or the independent DSMB from making any
determination or recommendation to terminate the trial.
The Sponsor obtained the randomisation code from the
company responsible for drug packing and conducted
three un-blinded analyses on different data sets prior to
the termination of the trial. In March 2008, by order of the
High Court of Justice, all claims against the LSHTM were
dismissed and the injunctions were discharged. All public
domain documentation is available on the trial coordinat-
ing centre web-site http://www.trialscoordinatingcen
tre.Lshtm.ac.uk/.
Randomisations
The 228 patients randomised to Anatibant or placebo
group (Figure 1) up to 1 November 2007 were recruited
from 15 hospitals in eight countries. There were protocol
violations in 11 patients. One patient had a normal CT
scan and therefore did not meet the inclusion criteria; two
patients were later found to be legal minors; three patients
received the trial treatment more than 8 hours after injury;
two patients did not receive the allocated treatment; one
patient did not complete the locally required consent pro-
cedure; one patient was given the trial treatment in the
wrong injection site (shoulder rather than abdomen or
thigh) and in one patient administration of the mainte-
nance dose was delayed. A total of 219 patients were ran-
domised using the IVRS method and 9 used a back-up
system which involved selecting the lowest numbered
treatment pack available at the hospital. The back-up sys-
tem was used to randomise patients for whom the trial
coordinating centre had granted a protocol pre-specified
waiver to one of the eligibility criteria, and in the event of
failure of the international free-phone system. TreatmentTrials 2009, 10:109 http://www.trialsjournal.com/content/10/1/109
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groups were approximately balanced with respect to base-
line characteristics (Table 1).
Both per protocol (PP) and intention to treat analyses
(ITT) were conducted. PP analysis is presented only for the
primary analysis (number and percentage of patients with
at least one SAE). ITT analysis is presented for all other
analyses since there were no material differences between
them.
Effects on Serious Adverse Events up to Day 15
There were 43 (26.4%) patients with at least one SAE
within two weeks of randomisation among the 163
patients allocated Anatibant (all doses combined), com-
pared with 11 (19.3%) among the 57 allocated placebo
(Table 2). There was no significant effect of Anatibant on
the risk of at least one SAE within two weeks (RR = 1.37
(0.76 to 2.46), 1 sided p= 0.19). There were no SAEs sus-
pected to be related to the study drug as judged by inves-
tigators.
Effect on all cause mortality
Vital status at two weeks following injury was known for
220 (96%) randomised patients. There were 31 (19.0%)
deaths in those allocated Anatibant (all doses combined),
compared with 9 (15.8%) among those allocated placebo
(RR = 1.20 (0.61 to 2.36), 1 sided p = 0.38).
Effect on Glasgow Coma Score
The mean GCS in patients allocated Anatibant (all doses
combined) was 12.48 compared with 9.73 among those
allocated placebo (a lower GCS signifies worse outcome).
Adjusting for baseline GCS score the difference in the
CONSORT Flowchart Figure 1
CONSORT Flowchart. Patients who withdrew from the trial and for whom final outcome measurements (GCS, HIREOS 
and DRS) were obtained, but earlier than scheduled, are classified as having discontinued the trial. Patients who withdrew 
from the trial without completing their final outcome measurements are classified as lost to follow up. Individuals who were 
lost to follow up do not contribute to the analyses; those who discontinued the trial contribute to this intention to treat 
analysis if data were available.
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Table 1: Baseline Characteristics.
High dose XY2405 Medium dose XY2405 Low dose XY2405 All doses XY2405 
combined
Placebo
Patients randomised: n 57 56 58 171 57
Age:
mean (SD) 35.9 (14.0) 37.6 (14.3) 35.5 (13.8) 36.3 (14.0) 36.4 (14.3)
median (min -- max) 33 (19 -- 65) 37 (18 -- 64) 32 (17 -- 61) 34 (17 -- 65) 34 (17 -- 64)
16 -- 39 (%) 36 (63.2) 32 (57.1) 35 (60.3) 103 (60.2) 35 (61.4)
40 -- 49 (%) 8 (14.0) 11 (19.6) 9 (15.5) 28 (16.4) 8 (14.0)
50 + (%) 13 (22.8) 13 (23.2) 14 (24.1) 40 (23.4) 14 (24.6)
Gender: n (%)
male 51 (89.5) 50 (89.3) 52 (89.7) 153 (89.5) 50 (87.7)
Time since injury:
mean (SD) 5.5 (1.7) 5.7 (1.9) 5.8 (1.8)*** 5.7 (1.8) 5.9 (1.6)
median (min -- max) 5.8 (1.4 -- 8.0) 5.8 (2.1 -- 10.8)* 5.8 (1.8 -- 8.6)* 5.8 (1.4 -- 10.8)* 6.2 (2.3 -- 8.0)
≤ 1 hr (%) 0 0 0 0 0
> 1hr - ≤ 3 hrs (%) 4 (7.0) 3 (5.4) 5 (8.6) 12 (7.0) 4 (7.0)
> 3hrs - ≤ 8 hrs (%) 53 (93.0) 52 (92.9) 50 (86.2) 155 (90.6) 53 (93.0)
> 8 hrs (%) 0 1 (1.8) 2 (3.4) 3 (1.8) 0
Glasgow Coma Score:
mean (SD) 7.4 (3.0) 7.7 (3.4) 7.6 (2.9) 7.6 (3.1) 7.5 (3.0)
median (min-max) 7 (3 -- 14)** 7 (3 -- 15)** 7 (3 -- 12) 7 (3 -- 15)** 8 (3 -- 12)
3 -- 5 (%) 17 (29.8) 15 (26.8) 17 (29.3) 49 (28.7) 18 (31.6)
6 -- 8 (%) 18 (31.6) 19 (33.9) 17 (29.3) 54 (31.6) 17 (29.8)
9 -- 12 (%) 21 (36.8) 21 (37.5) 24 (41.4) 66 (38.6) 22 (38.6)
>12 (%) 1 (1.8) 1 (1.8) 0 2 (1.2) 0
Glasgow Coma Motor 
Sub-score: n
mean (SD) 3.8 (1.5) 3.9 (1.8) 4.1 (1.5)*** 3.9 (1.6) 4.0 (1.7)
median (min-max) 4 (1 -- 6) 5 (1 -- 6) 5 (1 -- 6) 5 (1 -- 6) 5 (1 -- 6)
Pupil reactivity to light: 
n (%)
Not testable (%) 0 0 0 0 0
Neither (%) 11 (19.3) 6 (10.7) 4 (6.9) 21 (12.3) 6 (10.5)
Only one reactive 
(%)
3 (5.3) 8 (14.3) 11 (19.0) 22 (12.9) 7 (12.3)
Both reactive (%) 43 (75.4) 42 (75.0) 43 (74.1) 128 (74.9) 44 (77.2)
Body Mass Index:
mean (SD) 24.5 (4.0) 24.0 (2.8) 24.0 (3.1)*** 24.2 (3.3) 24.9 (2.9)
median (min-max) 24.2 (17.3 -- 39.4) 24.2 (18.1 -- 31.1) 23.4 (17.3-33.2) 23.9 (17.3 -- 39.4) 24.4 (19.7-34.6)
Temperature:
mean (SD) 36.7 (0.8)# 36.6 (0.7)# 36.6 (0.8)# 36.6 (0.8)# 36.6 (0.9)#
median (min-max) 36.9 (34.0 -- 38.9) 36.7 (33.7 -- 37.8) 36.8 (33.7 -- 38.3) 36.8 (33.7 -- 38.9) 36.8 (33.5 -- 39.4)
Systolic Blood Pressure:
mean (SD) 132.6 (26.7) 128.0 (21.4) 130.4 (20.6)*** 130.3 (23.0) 124.7 (22.7)
median (min-max) 130.0 (98.0-212.0) 130.0 (91.0-200.0) 129.0 (93.0-190.0) 130.0 (91.0-212.0) 125.0 (60.0-177.0)
* Three individuals had their first injection after 8 hours
** Two individuals had Glasgow coma scores >12 but fulfilled all other eligibility criteria. As per protocol (6.5.2) a waiver was granted to allow these 
individuals to be randomised.
*** 1 missing value for low dose
# 3 missing values for high dose, 2 missing values for medium dose, 1 missing value for low dose, 1 missing value for placeboTrials 2009, 10:109 http://www.trialsjournal.com/content/10/1/109
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means (δ) was -0.55 [95% bootstrap CI (-1.42 to 0.59)], a
difference that was not statistically significant (p > 0.05).
Effect on Disability Rating Scale
The mean DRS among patients allocated Anatibant (all
doses combined) was 11.18 compared with 9.73 among
those allocated placebo (a higher DRS signifies a worse
outcome). Adjusting for baseline GCS score the (non-sta-
tistically significant, p > 0.05) difference in the means (δ)
was 1.61 [95% bootstrap CI (-1.16 to 4.23)].
Effect on HIREOS
The mean HIREOS among patients allocated Anatibant
(all doses combined) was 3.94 compared with 3.54
among those allocated placebo (a higher HIREOS signi-
fies a worse outcome). Adjusting for baseline GCS score
the (non-statistically significant, p > 0.05) difference in
the means (δ) was 0.42 [95% bootstrap CI (-0.08 to
0.86)].
Skin reactions at injection sites
Of patients who received Anatibant (all doses combined),
11.7% developed erythema at an injection site that was
classified as moderate, intense or very intense. There were
no such reactions in the placebo group (1 sided P =
0.003).
Un-blinding
There was no emergency un-blinding of randomised
patients.
Discussion
Principal findings
Our intention was to randomise 400 patients to this phase
II trial of Anatibant in patients with traumatic brain
injury. Had we done so, we would have had more than
90% power to detect a doubling in the number of patients
with one or more SAEs among patients on active treat-
ment. In fact, we were only able to randomise 228
patients and as a result the trial is underpowered. The sta-
tistically non-significant increase in the proportion of
patients with at least one SAE that we observed is consist-
ent with a sizeable increase or a modest reduction. We
also observed statistically non-significant increases in
mortality and morbidity.
Strengths and limitations of the study
We conducted an international multi-centre randomised
controlled trial of an emergency treatment for traumatic
brain injury. Despite the well documented challenges of
recruiting patients in emergency situations, patient
recruitment was rapid and had it not been prematurely
terminated the trial is likely to have reached its planned
sample size of 400 patients. Allocation was well concealed
through the use of central computerised telephone ran-
domisation. Although the use of matching placebo
helped to ensure that outcome assessment was blind to
treatment allocation, the subcutaneous administration of
Anatibant was associated with an increase in local skin
reactions at the injection site which could have un-
blinded treatment allocation in some cases. Skin reactions
are unlikely to have biased assessment of all cause mortal-
ity, but the extent to which they might have biased the
assessment of more subjective outcomes is open to ques-
tion. There was minimal loss to follow up.
Although the TSC temporarily stopped recruitment in
response to patient safety concerns from the DSMB, when
the data on all randomised patients were reviewed, it was
recommended that the trial could continue. Stopping
recruitment until the data on all randomised patients
could be represented to the DSMB, ensured that patient
safety was the prime consideration. It would be inappro-
priate to conclude that this temporary stop was unjusti-
fied, since even extreme differences in patient outcome
can occur by chance alone.
The primary outcome measure was the proportion of
patients with one or more SAEs. In the context of critical
illness however, the usual International Conference on
Harmonisation Good Clinical Practice (ICH GCP) defini-
tion of an SAE [14] is problematic [15], since SAEs are the
norm rather than the exception. For this reason, the ICH
definition of SAE was made more context specific and
medical occurrences which are expected in the course of
the natural history of TBI (for example variations in
intracranial pressure), or which are known to occur during
routine diagnostic or therapeutic procedures (for example
pain after surgery), were excluded. Our use of this revised
definition may have resulted in some under-reporting.
However, our approach to the reporting of SAEs in the
context of critical illness has been used before [16]. Due to
the decision to withdraw funding and the subsequent pre-
mature termination of the trial, this study was underpow-
ered. It is unknown to the authors whether the decision to
withdraw funding was influenced by the unscheduled un-
blinded analyses.
The BRAIN trial in relation to other trials
Although this is the largest trial of a Bradykinin B2 recep-
tor antagonist in TBI conducted so far, it was small, and
even in aggregate the total number of participants in clin-
ical trials of B2 Receptor antagonists is less than 400
patients. The pooled relative risk for death from all trials
combined is 0.84 (95% CI = 0.55 to 1.29) which is con-
sistent with a modest increase or a modest decrease in the
risk of death (Figure 2).
Conclusion
Although with 228 patients randomised this trial was
underpowered to detect even large increases in the risk of
adverse events, it provides no reliable evidence of harmTrials 2009, 10:109 http://www.trialsjournal.com/content/10/1/109
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Table 2: Adverse Events and outcomes by intention to treat other than where otherwise indicated.
High dose XY2405 Medium dose XY2405 Low dose XY2405 All doses XY2405 
combined
Placebo
Number of patients 57 56 58 171 57
Number (%) of patients 
with at least one serious 
adverse event
15/57 (26.3%) 15/52# (28.8%) 13/54# (24.1%) 43/163# (26.4%)
RR = 1.37 (0.76, 2.46)
1 sided P = 0.19
11/57 (19.3%)
Number (%) of patients 
with at least one serious 
adverse event 
(Per Protocol analysis)
15/56 (26.8%) 15/48 (31.3%) 12/46 (26.1%) 42/150 (28.0%)
RR = 1.48 (0.80, 2.74)
1 sided P = 0.13
10/53 (18.9%)
Number (%) of patients 
with at least one serious 
adverse event which is 
suspected to be related to 
study drug
00 0 0 0
Number of serious adverse 
events#
0 42 (73.3%) 37 (71.2%) 41 (75.9%) 120 (73.6%) 46 (80.7%)
1 12 (21.1%) 8 (15.4%) 11 (20.4%) 31 (19.0%) 7 (12.3%)
2 2 (3.5%) 5 (9.6%) 1 (1.9%) 8 (4.9%) 3 (5.3%)
3+ 1 (1.8%) 2 (3.8%) 1 (1.9%) 4 (2.5%) 1 (1.8%)
Total number SAEs 19 25 16 60 16
Glasgow Coma Score at 
day 15
12.54 12.63 12.29 12.48 13.00
δ = -0.36
P > 0.05
(-1.56, 0.92)
δ = -0.48
P > 0.05
(-1.55, 0.78)
δ = -0.80
P > 0.05
(-2.00, 0.53)
δ = -0.55,
P > 0.05
(-1.42, 0.59)
Ref
10.70* 10.60* 10.74* 10.68*
δ = -0.78 P > 0.05
(-2.08, 0.61)
11.42*
Ref
HIREOS at day 15 3.98 3.89** 3.92 3.93 3.54
δ = 0.43 P > 0.05
(-0.17, 1.05)
δ = 0.42 P > 0.05
(-0.19, 0.98)
δ = 0.39 P > 0.05
(-0.21, 0.98)
δ = 0.41 P > 0.05
(-0.06, 0.89)
Ref
Disability Rating Scale at 
day 15
11.26 10.61** 11.63 11.18 9.73
δ = 1.17 P > 0.05
(-2.70, 4.60)
δ = 1.46 P > 0.05
(-1.60, 4.80)
δ = 2.22 P > 0.05
(-1.25, 5.66)
δ = 1.62 P > 0.05
(-1.16, 4.23)
Ref
14.88* 14.63* 14.69* 14.74*
δ = 1.97 P > 0.05
(-1.27, 5.00)
12.93*
Ref
All cause mortality up to 
day 15: (%)
11/57 (19.3%) 11/52#(21.2%) 9/54# (16.7%) 31/163# (19.0%)
RR = 1.20 (0.61, 2.36)
1 sided P = 0.37
9/57 (15.8%)
Number (%) of patients 
with erythema at injection 
site classified as moderate, 
intense or very intense.
12/57 (21.1%) 3/52# (5.8%) 4/54# (7.4%) 19/163# (11.7%)
1 sided P = 0.003
0/57 (0.0%)
δ's represent differences between mean levels in each group and the placebo group, adjusted for baseline GCS scores using ANCOVA. 95% CI's are 
non-parametric bias-corrected and accelerated bootstrap confidence intervals (calculated using 2,000 replications).
The statistical significance of differences between groups in 15-day mortality rates and numbers of patients with erythema at injection site classified 
as moderate, intense or very intense are obtained using Fisher's exact test.
# denominator does not include individuals who were excluded from analyses
* with deaths coded as GCS = 3 and DRS coded as 30
** includes data on one individual who withdrew consent except for HIREOS & DRSTrials 2009, 10:109 http://www.trialsjournal.com/content/10/1/109
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and no suspected unexpected serious adverse events
(SUSARs) were reported.
The litigation delayed the conduct of the trial and incurred
a considerable opportunity cost to the trial investigators.
At a time when universities are encouraged to collaborate
with industry in drug development the risk of litigation
must be considered carefully.
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